Naproxen: Difference between revisions
(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)) |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 62: | Line 62: | ||
|?Has Route=Route | |?Has Route=Route | ||
|?Has Population=Population | |?Has Population=Population | ||
|format= | |format=table | ||
|headers=plain | |headers=plain | ||
| | |mainlabel=- | ||
|sort=Has Indication | |sort=Has Indication | ||
|limit=50 | |limit=50 | ||
Latest revision as of 21:56, 20 March 2026
Administration
- Type: NSAID
- Dosage Forms: 250mg, 500mg
- Routes of Administration: PO
- Common Trade Names: Aleve
Adult Dosing
- 500mg PO BID OR 250mg q6-8h
Pediatric Dosing
- 5mg/kg BID
Special Populations
- Pregnancy Rating: C
- Lactation risk: infant risk minimal
Renal Dosing
- Adult: Not recommended if CrCl <30
- Pediatric:
Hepatic Dosing
- Adult: use lowest effective dose
- Pediatric:
Contraindications
- Allergy to class/drug
- peri-CABG
Adverse Reactions
Serious
- GI bleed, gastric ulcer
- Nephrotoxicity
- Angioedema
- Bronchospasm
- CHF, pulmonary edema
- Thrombocytopenia, aplastic anemia, hemolytic anemia, agranulocytosis
- Vasculitis
- SJS/TEN
- Hepatotoxicity (hepatitis, liver failure)
- Aseptic meningitis, seizure
Common
- Nausea, heartburn, constipation
- Edema
- Ecchymosis
- Headache
- Ototoxicity
Pharmacology
- Half-life: 12-17 hours
- Metabolism:
- Excretion: Renal
Mechanism of Action
- NSAID
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Acute pain management | 250 mg PO q6-8h or 500-1000 mg PR q6-8h | Non-opioid analgesic (NSAID) | PO/PR | Adult |
| Gout and pseudogout | 500mg BID x 3-7 days | First-line NSAID option for acute gout | PO | Adult |